Skip to main content

Journal Club

Cerebrovascular

Curative cerebrovascular reconstruction with the Pipeline embolization device: the emergence of definitive endovascular therapy for intracranial aneurysms

Journal of NeuroInterventional Surgery | 2009

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1136/jnis.2009.000083

PMID

N/A

PICO

Population

Patients with large, wide-necked, or otherwise difficult intracranial aneurysms discussed in early Pipeline experience and supporting literature.

Intervention

Parent-artery reconstruction with the Pipeline embolization device.

Comparator

Conventional endosaccular coil embolization and stent-assisted coiling strategies.

Outcomes

Durable aneurysm occlusion, recurrence or recanalization, branch-vessel patency, and early procedural complications.

Design

Type

Narrative device review with early multicenter prospective experience

Randomized

No

Multicenter

Yes

Blinded

N/A

Follow-up

6 months to 1 year in the early studies summarized

Primary endpoint

Complete angiographic aneurysm occlusion after parent-artery reconstruction.

Secondary endpoints

  • Recanalization and recurrence after coiling
  • Periprocedural stroke and in-stent stenosis in early Pipeline studies
  • Patency of covered branch vessels and symptom resolution

Practice impact

What this means

This paper argues that flow diversion with Pipeline can solve a problem that coiling often does not: durable reconstruction of the diseased parent artery in large or wide-necked aneurysms. The early results are promising, especially for sidewall internal carotid aneurysms, but the evidence in this article is still mostly early series and proof-of-concept work.

Bottom line

Pipeline looks like a serious reconstructive option for selected difficult aneurysms, but this paper alone supports adoption only in experienced centers and not as blanket replacement for standard coiling or clipping.

Strength of evidence

low

Recommendation

consider change

Why it matters

  • The failure rates of conventional coiling in difficult aneurysms are substantial in the cited literature.
  • Early Pipeline data show high occlusion rates in selected sidewall aneurysms.
  • The evidence base in this article remains early, indirect, and sensitive to operator and case selection.

What would change my mind

  • A larger comparative study showing Pipeline keeps its occlusion advantage without excess stroke or branch occlusion.
  • Long-term multicenter follow-up clarifying durability and antiplatelet requirements across aneurysm subtypes.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

The article is a narrative review that relies heavily on early case series, compassionate-use reports, and one small prospective trial.

Confounding

Comparisons with coiling are indirect and depend on different aneurysm anatomies, eras, and operator experience.

Missing data

Long-term durability and antiplatelet strategy were still evolving, and branch-vessel safety data were based on relatively short follow-up.

Multiplicity

The review combines device mechanics, animal data, single cases, and early clinical cohorts without a formal comparative framework.

Notes

  • Most Pipeline efficacy data came from sidewall internal carotid aneurysms rather than all aneurysm types.
  • The article reads as proof-of-concept rather than definitive comparative effectiveness evidence.
  • The paper itself notes uncertainty around long-term thrombogenicity and antiplatelet needs.

Stats check

NNT

N/A

Effect sizes

  • In the cited coiling series of 501 aneurysms, complete angiographic occlusion at 1 year was 38.3%.
  • In the PITA trial, 28 of 30 patients with 6-month follow-up were angiographically cured, or 93%.

Absolute effects

  • The same coiling series reported 33.6% recanalization and 20.7% major recurrences over 1 year, rising to 48.6% after retreatment.
  • The PITA trial treated 31 patients and had 2 strokes, for an overall complication rate of 6%.

Concerns

  • The strongest Pipeline numbers come from a small nonrandomized early trial.
  • The comparator data come from outside cohorts rather than head-to-head testing.
  • Device performance may differ by aneurysm morphology, vessel territory, and antiplatelet regimen.

External validity

Who it applies to

Neurointerventional teams considering flow diversion for large, wide-necked, or sidewall aneurysms not well served by coiling alone.

Who it does not

Teams seeking mature comparative evidence for all aneurysm locations, especially bifurcation lesions and settings with limited antiplatelet support.

Generalizability notes

  • The clearest early efficacy signal was in sidewall internal carotid aneurysms.
  • Results from compassionate-use and early-adopter centers may overestimate performance in broader practice.
  • Covered branch-vessel safety may not translate uniformly across posterior circulation or perforator-rich anatomy.

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 6

claim_id

stats_check.effect_sizes

locator

p. 1

claim_id

practice_impact.bottom_line

locator

p. 6

quote

Pipeline reproducibly provides a definitive, durable and curative endovascular treatment option

Metadata

Generated at

2026-03-08T03:10:00Z

Version

manual-pdf-repair-v1